TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Total brain parenchymal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of good-quality blastocysts on Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse at 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Neurocognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Auditory Processing Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reward Sensitivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in time to detection of probiotic strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in time to non-detection (persistence) of probiotic strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic Respiratory Questionnaire Self-Reported (CRQ-SR)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Beck Depression Inventory 2nd edition-Fast Screen (BDI-FS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perceived dyspnea Visual Analogue Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Unscheduled Healthcare Visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in the Level of Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Flexion/extension deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Laxity in hyperextension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prehension force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total serum concentrations of cefixime
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability assessed by laboratory monitoring
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic curves of cefixime levels versus time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Functional Gastrointestinal Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: laboratory-confirmed influenza or other respiratory viral infection
Endpoint domain: Adverse events/effects
Primary endpoint: Measurement of pulsative hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Start the Anaesthetic Effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic Effect After Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molecular Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heterochronous distant metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Asthma Control Questionnaire (ACQ) Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptance of referral to cardiac rehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Total Disposition Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression and anxiety severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Endotracheal Intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Aztreonam (ATM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Avibactam (AVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve From Time Zero up to 6 Hours (AUC[0-6]) for Aztreonam (ATM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of lower-extremity lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain ratings using the visual analog scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methadone plasma pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants That Relapsed to Drinking at 4 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Drinking Days in 4 Months Post Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Standard Drinks Per Drinking Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant Assessment of Present Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-report of pre-exposure prophylaxis (PrEP) use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: TMJ proprioception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in physical activity: objective
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in physical activity: self-reported
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reversal of anticoagulant effects of heparin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of home health clinician visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of BCTs used by parent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent perception of general conflict between parent and child
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 5-year Recurrence-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in subjective hunger questionnaire (Visual Analog Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum satiety and hunger hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Social cognitive performance
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Changes in fat body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of subjects referred for second-line therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Spinal Cord Volume Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Spinal Cord Atrophy Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Positive cases of coronavirus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area Under the Time Concentration curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With early onset Preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Staging of pancreatic cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maternal antibody concentration in newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Pain Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum decrease in Respiratory Status Scale© total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bone erosion change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in the Summed score on the Heinrich-Carpenter Quality of Life Measure
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Measurement of Portal flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Shoulder function (Constant Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-Mullerian hormone (AMH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Follicle Stimulation Hormone (FSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of endothelial cell loss (ECL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diaphragm function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants Discontinuing Study Treatment due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Pulmonary Transit Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Receipt of 2nd Dose of the Influenza Vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of grade 3-4 mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: duration of abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Treatment Failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Patient Activation Measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the International Prostate Symptom Score (IPSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Malaria Defined as Positive Placental Blood Smear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of Malaria Defined as Positive Placental Blood PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Global Ocular Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall ease of use of device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Common treatment site responses (CTR's)
Endpoint domain: Adverse events/effects
Primary endpoint: NIH Stroke Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Fentanyl consumption by patient-controlled analgesia
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Numerical rating score of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence of TSST-1 Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean PTH reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of Thigh Circumference From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numbness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Shunt Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Botulinum Toxin in Spastic Neuropathic Bladder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of Device- or Procedure-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Correctly Identified Photos by Blinded Reviewers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with add-on solifenacin treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women receiving immediate postpartum long-acting contraception
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Active treatment-free interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) for citrulline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Non-inferiority of cfDNA-based genotyping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Radiation related toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Patient experience and anxiety related to Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Microvascular obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the plasma concentration time curve (AUC) of levonorgestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of levonorgestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve (AUC) of norethindrone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of norethindrone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve (AUC) of etonogestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Benefit (CB) Assessed by Complete Response (CR), Partial Response (PR) or Stable Disease (SD) for at Least 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Confocal image characteristics of biliary strictures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in Modified Scale for the Assessment of Negative Symptoms (SANS 1-22 Composite Score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tumor tissue concentration of cisplatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Normal tissue concentration of cisplatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postoperative Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peri-implant Probing depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rapid virological response (undetected HCV RNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to first occurrence of cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Change in CFQR Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: termination from treatment due to a suspected adverse drug reaction (SADR)
Endpoint domain: Adverse events/effects
Primary endpoint: adverse events (AEs) or laboratory toxicities of Grade 3 or higher severity
Endpoint domain: Adverse events/effects
Primary endpoint: Knee joint cartilage degeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of grade 3 or 4 transaminase elevations
Endpoint domain: Adverse events/effects
Primary endpoint: patients without tumor progression
Endpoint domain: Mortality/survival
Primary endpoint: collateral tumor vessel growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Occurrence rate of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidents of secondary hip fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Negative Pressure Maintenance at Nominal 80 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dressing Wear Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exudate Management (Occurrence of Exudate Leaks)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Neurocognitive test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of HPV vaccination
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Plasmatic concentration of anti-proteasome autoantibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression profile change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women with bleeding controlled
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-weighted Sum of the Pain Intensity Difference (SPID24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of ibrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of Contracting Procedures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Length of Time to Site IRB Approval
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Length of Time to 1st Participant Enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Development of endocrine dysfunction (diabetes & prediabetes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With a Diagnosis of a Cognitive Impairment Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Any Referral for Further Evaluation/Management of Potential Cognitive Impairment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With at Least One Follow-up Visit for Additional Investigation of a Cognitive Impairment Disorder
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Appetite profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma levels of cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: freedom of local failure
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Adapted Mayo Score (MCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint Position Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Brain Alpha5-Containing GABA-A Receptors Occupied by RO7017773
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentrations of RO7017773
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood loss during vaginal deliveries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Off time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Step Length Asymmetric Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the insulin aspart curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intensive care unit admission
Endpoint domain: Mortality/survival
Primary endpoint: Mismatch negativity (MMN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in 24-hour brachial blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of major error in inhalation system use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: actual neural activation in brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Succinylacetone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Virologic Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with a Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs), Grade 3 or Higher Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Visual Analogue Scale (VAS) results at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Range of Motion (ROM) results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Subjects With Positive LUCENTIS® Retreatment Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of total enteroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of respiratory diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: clearance of viral DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cell mediated response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Patients Achieving Glycemic Target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Minimal Weight Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes